Trends in Anesthesiology

Cumberland Pharmaceuticals Inc. has announced U.S. Food and Drug Administration (FDA) approval of Caldolor^® (intravenous ibuprofen, or IVIB) as a standard treatment for pain and fever across various patient demographics. Caldolor offers multimodal pain management, with clinical studies demonstrating IVIB’s significant efficacy in reducing temperature compared to placebo or acetaminophen, its ability to alleviate postsurgical pain when administered before surgery, potentially reducing opioid use, and its efficacy in minimizing opioid requirements for acute pain management in the emergency department. IVIB is the only nonopioid injectable analgesic approved for infants as young as 3 months old, positioning it as a possible foundational component of multimodal pain regimens. An April press release emphasizes the importance of judicious pain management, particularly amid the prevalent opioid prescription trend and its associated risks of dependence and misuse.

Source: asamonitor.pub/3U2eNfU